Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Italian Institute for Genomic Medicine, IIGM, 10060 Candiolo, Italy.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):e163-e174. doi: 10.1210/clinem/dgad468.
MicroRNA-191-5p regulates key cellular processes involved in the pathogenesis of diabetic complications such as angiogenesis, extracellular matrix deposition, and inflammation. However, no data on circulating microRNA-191-5p in the chronic complications of diabetes are available.
To assess whether serum levels of microRNA-191-5p were associated with micro- and macrovascular disease in a large cohort of subjects with type 1 diabetes mellitus (DM1) from the EURODIAB Prospective Complication Study.
Levels of microRNA-191-5p were measured by quantitative PCR in 420 patients with DM1 recruited as part of the cross-sectional analysis of the EURODIAB Prospective Complication Study. Cases (n = 277) were subjects with nephropathy and/or retinopathy and/or cardiovascular disease (CVD). Controls (n = 143) were patients without complications. Logistic regression analysis was performed to evaluate the potential independent association of microRNA-191-5p levels with chronic complications of diabetes.
Levels of microRNA-191-5p were significantly reduced (P < .001) in cases compared with controls even after adjustment for age, sex, and diabetes duration. Logistic regression analysis revealed that microRNA-191-5p was negatively associated with a 58% reduced odds ratio (OR) of chronic diabetes complications, specifically CVD, micro-macroalbuminuria, and retinopathy (OR, 0.42; 95% CI, 0.23-0.77), independent of age, sex, physical activity, educational levels, diabetes duration, glycated hemoglobin, total insulin dose, hypertension, smoking, total cholesterol, albumin excretion rate, estimated glomerular filtration rate, serum vascular cell adhesion molecule-1, and tumor necrosis factor-α. Analyses performed separately for each complication demonstrated a significant independent association with albuminuria (OR, 0.36; 95% CI, (0.18-0.75) and CVD (OR, 0.34; 95% CI, 0.16-0.70).
In DM1 subjects, microRNA-191-5p is inversely associated with vascular chronic complications of diabetes.
MicroRNA-191-5p 调节与糖尿病并发症发病机制相关的关键细胞过程，如血管生成、细胞外基质沉积和炎症。然而，目前尚无关于糖尿病慢性并发症中循环 microRNA-191-5p 的数据。
在来自 EURODIAB 前瞻性并发症研究的大型 1 型糖尿病（DM1）患者队列中，评估血清 microRNA-191-5p 水平与微血管和大血管疾病的相关性。
通过定量 PCR 测量 420 名 DM1 患者的 microRNA-191-5p 水平，这些患者是 EURODIAB 前瞻性并发症研究的横断面分析的一部分。病例（n=277）为合并肾病和/或视网膜病变和/或心血管疾病（CVD）的患者。对照组（n=143）为无并发症的患者。进行逻辑回归分析以评估 microRNA-191-5p 水平与糖尿病慢性并发症的潜在独立相关性。
即使在调整年龄、性别和糖尿病病程后，病例组的 microRNA-191-5p 水平仍明显降低（P＜0.001）。逻辑回归分析显示，microRNA-191-5p 与慢性糖尿病并发症的风险降低 58%相关，特别是 CVD、微量-大量白蛋白尿和视网膜病变（OR，0.42；95%CI，0.23-0.77），独立于年龄、性别、体育活动、教育水平、糖尿病病程、糖化血红蛋白、总胰岛素剂量、高血压、吸烟、总胆固醇、白蛋白排泄率、估计肾小球滤过率、血清血管细胞黏附分子-1 和肿瘤坏死因子-α。对每种并发症分别进行的分析表明，与白蛋白尿（OR，0.36；95%CI，（0.18-0.75）和 CVD（OR，0.34；95%CI，0.16-0.70）均存在显著独立相关性。
在 DM1 患者中，microRNA-191-5p 与糖尿病的血管慢性并发症呈负相关。
